The 05 52 pill is an immediate-release Oxycodone Hydrochloride 5 mg tablet manufactured by Mallinckrodt Pharmaceuticals. It is a potent semi-synthetic opioid analgesic classified as a Schedule II controlled substance in the United States due to its high potential for dependence, misuse, and addiction.
Pill Identification & Physical Characteristics
Property – Description
- Active Ingredient – Oxycodone Hydrochloride (5 mg)
- Imprint –
05 52(with a vertical bisect line separating 05 and 52) on one side;Minside a square box on the reverse - Shape & Color – Round, convex tablet; White
- Size – Approximately 6 mm in diameter
- Drug Class – Opioid Agonist / Narcotic Analgesic
- Manufacturer – Mallinckrodt Pharmaceuticals
Mechanism of Action
Oxycodone is a full opioid agonist that selectively binds to opioid receptors throughout the central nervous system (brain and spinal cord) and peripheral tissues.
- Pain Transmission Inhibition: Activation of opioid receptors inhibits the release of neurotransmitters (such as substance P and glutamate) from primary nociceptive afferents, blocking the ascending pain signaling pathways.
- Perception Modulation: It stimulates descending inhibitory pain pathways and alters the brain’s emotional and cognitive response to pain, inducing analgesia and sedation.
- Reward Pathway Activation: Opioid receptor activation stimulates dopamine release in the mesolimbic pathway, creating feelings of euphoria, which drives the potential for psychological dependence and addiction.
Indications & Dosage
Indications
- Management of acute, moderate-to-severe pain where non-opioid analgesics (such as NSAIDs or acetaminophen) are ineffective, contraindicated, or inadequate (e.g., acute post-surgical recovery, trauma).
- Immediate-release oxycodone is not intended for mild pain or as an “as-needed” (PRN) treatment for long-term chronic pain unless part of a specialized palliative care plan.
General Adult Dosing
- Opioid-Naïve Patients: Typically initiated at 5 mg to 15 mg orally every 4 to 6 hours as needed for pain.
- Administration: Must be swallowed whole with water. It can be taken with or without food, though taking it with food or milk may reduce gastrointestinal upset.
- Discontinuation: Patients taking oxycodone regularly for more than a few days must undergo gradual dose tapering under medical supervision to avoid acute opioid withdrawal symptoms.
Side Effects
Common Adverse Reactions
- Drowsiness, dizziness, and sedation
- Constipation and dry mouth
- Nausea, vomiting, and abdominal discomfort
- Pruritus (itching) and sweating
- Headache
Severe & Life-Threatening Reactions
- Respiratory Depression: Critically slow, shallow, or irregular breathing.
- Severe Hypotension & Bradycardia: Fainting, severe dizziness, or orthostatic drop in blood pressure.
- Serotonin Syndrome: When combined with serotonergic drugs (agitation, hyperthermia, tremor, hyperreflexia).
- Adrenal Insufficiency: Chronic opioid use can decrease cortisol production, causing extreme fatigue, anorexia, and dizziness.
- Severe Allergic Reactions: Anaphylaxis, angioedema, or rash.
Precautions & Drug Interactions
- Central Nervous System Depressants: Concurrent use of oxycodone with benzodiazepines, sedatives, muscle relaxants, or alcohol dramatically increases the risk of profound sedation, respiratory arrest, coma, and death.
- CYP3A4 and CYP2D6 Interactions: Oxycodone is primarily metabolized by CYP3A4 and CYP2D6 enzymes. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase oxycodone blood concentrations, raising overdose risk. CYP3A4 inducers (e.g., rifampin, carbamazepine) reduce efficacy.
- Pre-existing Respiratory Conditions: Extreme caution is required in patients with chronic obstructive pulmonary disease (COPD), severe asthma, sleep apnea, or compromised respiratory drive.
- Gastrointestinal Impairment: Contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
- Pregnancy & Lactation: Prolonged use during pregnancy can lead to Neonatal Opioid Withdrawal Syndrome (NOWS). Oxycodone passes into breast milk and can cause respiratory depression in nursing infants.
Black Box Warnings
- Critical Safety Warnings:
- Addiction, Abuse, and Misuse: Carries a significant risk of opioid use disorder, overdose, and fatal respiratory depression even when taken as prescribed.
- Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur, with the highest risk at therapy initiation or following dosage escalation.
- Accidental Ingestion: Accidental ingestion of even one tablet, especially by children, can result in a fatal overdose.
- Concomitant Use with Benzodiazepines or Alcohol: Deep sedation, coma, and respiratory death may occur if combined.
- Opioid Overdose Reversal: Patients and caregivers should be educated on the availability and administration of naloxone for emergency treatment of known or suspected opioid overdose.